

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treating or inhibiting obesity in a patient, comprising identifying a compound which inhibits de novo lipogenesis in a mammal, wherein said compound is identified by measuring the effect of at least one candidate compound on the carboanhydrase activity in a mammal, and selecting a compound which inhibits activity of at least one mammalian carboanhydrase, and administering an effective obesity inhibiting amount of said compound to said patient, with the proviso that said compound is not topiramate.

2. (canceled)

3. (previously presented) A method according to claim 1, wherein said compound inhibits activity of at least one mammalian carboanhydrase in an *in vitro* enzyme activity test, and reduces an amount of metabolic products formed in the citric acid cycle of isolated living mammalian cells.

4. (Original) A method according to claim 1, wherein said compound is administered to the patient over a period of at least six weeks.

5-6. (canceled)